Paolo Tombesi
2017 - INSMED
In 2017, Paolo Tombesi earned a total compensation of $1.9M as Chief Financial Officer at INSMED.
Compensation breakdown
| Bonus | $40,000 |
|---|---|
| Non-Equity Incentive Plan | $277,400 |
| Option Awards | $1,300,046 |
| Salary | $253,750 |
| Other | $12,087 |
| Total | $1,883,283 |
Tombesi received $1.3M in option awards, accounting for 69% of the total pay in 2017.
Tombesi also received $40K in bonus, $277.4K in non-equity incentive plan, $253.8K in salary and $12.1K in other compensation.
Rankings
In 2017, Paolo Tombesi's compensation ranked 5,795th out of 14,666 executives tracked by ExecPay. In other words, Tombesi earned more than 60.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,795 out of 14,666 | 61st |
Division Manufacturing | 2,105 out of 5,772 | 64th |
Major group Chemicals And Allied Products | 657 out of 2,075 | 68th |
Industry group Drugs | 506 out of 1,731 | 71st |
Industry Pharmaceutical Preparations | 401 out of 1,333 | 70th |
Source: SEC filing on April 5, 2018.
Tombesi's colleagues
We found seven more compensation records of executives who worked with Paolo Tombesi at INSMED in 2017.
2017
William Lewis
INSMED
Chief Executive Officer
2017
Roger Adsett
INSMED
Chief Commercial Officer
2017
Christine Pellizzari
INSMED
Chief Legal Officer
2017
S Schaeffer
INSMED
Chief People Strategy Officer
2017
Paul Streck
INSMED
Chief Medical Officer
2017
John Goll
INSMED
Former Principal Financial Officer
2017
Andrew Drechsler
INSMED
Chief Financial Officer
News
Turning Point Therapeutics CEO Athena Countouriotis' 2021 pay rises 11% to $17M
April 29, 2022
Epizyme CEO Robert Bazemore's 2020 pay jumps 103% to $8.5M
April 29, 2021
Epizyme CEO Robert Bazemore's 2019 pay rises 14% to $4.2M
April 17, 2020
INSMED CEO William Lewis' 2019 pay jumps 21% to $7.2M
March 31, 2020
INSMED CEO William Lewis' 2018 pay jumps 37% to $5.9M
April 4, 2019